急性髓系白血病相关基因突变的研究进展  

Progress of acute myeloid leukemia related gene mutations

作　　者：李芸芸 吴涛 Li Yunyun;Wu Tao(The First Clinical Medical College of Gansu University of Chinese Medicine,Lanzhou 730000,China;Department of Hematology,the 940th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army,Lanzhou 730050,China)

机构地区：[1]甘肃中医药大学第一临床医学院,兰州730000 [2]解放军联勤保障部队第九四〇医院血液科,兰州730050

出　　处：《白血病.淋巴瘤》2025年第2期125-128,共4页Journal of Leukemia & Lymphoma

基　　金：甘肃省创新基地和人才计划(21JR7RA015);甘肃省重点研发计划(22YF7FA106);联勤保障部队第九四〇医院血液病医学研究中心项目(2021yxky078)。

摘　　要：急性髓系白血病(AML)是具有高度异质性的侵袭性恶性肿瘤,其主要特征是白血病原始细胞的快速增殖、凋亡失调和分化受损,可在任何年龄发病。AML的发展与演变的背后隐藏着其病因复杂性、机制多样性、细胞遗传学和基因组学的变异性,其中一些特定的细胞遗传学和基因组学的异常造成了临床AML患者的高复发率以及耐药率。目前,突变基因的临床应用已成为临床医学中的一个备受关注的热点领域。文章通过分析常见突变基因的作用以及分子靶向治疗,以期对临床治疗提供帮助。Acute myeloid leukemia(AML)is an aggressive malignant tumor with high heterogeneity.It is characterized by rapid proliferation,dysapoptosis and impaired differentiation of leukemic blast cells.It can develop at any age.The complexity of the etiology,the diversity of mechanisms,and the variability of cytogenetics and genomics hid behind the development and evolution of AML,among which some specific cytogenetic and genomic abnormalities cause the high recurrence rate and drug resistance rate of clinical AML patients.At present,the clinical application of mutated genes has become a hot field in clinical medicine.This paper reviews the role of common mutated genes and molecular targeted therapy in order to provide help for clinical treatment.

关 键 词：白血病 髓样 急性 突变 基因 二代测序 预后 

分 类 号：R73[医药卫生—肿瘤]